Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease
- 24 January 2011
- Vol. 60 (7), 923-929
- https://doi.org/10.1136/gut.2010.232025
Abstract
Introduction The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease. Aims and methods To assess the impact of FOS in patients with active Crohn's disease using an adequately powered randomised double-blind placebo-controlled trial with predefined clinical, microbiological and immunological end points. Patients with active Crohn's disease were randomised to 15 g/day FOS or non-prebiotic placebo for 4 weeks. The primary end point was clinical response at week 4 (fall in Crohn's Disease Activity Index of ≥70 points) in the intention-to-treat (ITT) population. Results 103 patients were randomised to receive FOS (n=54) or placebo (n=49). More patients receiving FOS (14 (26%) vs 4 (8%); p=0.018) withdrew before the 4-week end point. There was no significant difference in the number of patients achieving a clinical response between the FOS and placebo groups in the ITT analysis (12 (22%) vs 19 (39%), p=0.067). Patients receiving FOS had reduced proportions of interleukin (IL)-6-positive lamina propria DC and increased DC staining of IL-10 (pF prausnitzii between the groups at baseline or after the 4-week intervention. Conclusion An adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn's disease, despite impacting on DC function. ISRCTN50422530.Keywords
This publication has 35 references indexed in Scilit:
- Probiotic and prebiotic use in patients with inflammatory bowel diseaseInflammatory Bowel Diseases, 2010
- Dietary poorly absorbed, short‐chain carbohydrates increase delivery of water and fermentable substrates to the proximal colonAlimentary Pharmacology & Therapeutics, 2010
- Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors?Gastroentérologie Clinique et Biologique, 2009
- Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patientsProceedings of the National Academy of Sciences of the United States of America, 2008
- Specific Microbiota Direct the Differentiation of IL-17-Producing T-Helper Cells in the Mucosa of the Small IntestineCell Host & Microbe, 2008
- Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trialsProceedings Of The Nutrition Society, 2007
- A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humansEuropean Journal of Clinical Nutrition, 2007
- Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal HomeostasisCell, 2004
- Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic CellsScience, 2003
- On the presence of Inulin and Oligofructose as natural ingredients in the western dietCritical Reviews in Food Science and Nutrition, 1995